Antiangiogenesis: a possible treatment option for prostate cancer?
With a need for effective treatment modalities in prostate cancer, angiogenesis is a likely target for the interference of tumor progression. Angiogenesis promotes the vasculature of a tumor, allowing for tumor progression and for cancer cells to metastasize and spread throughout the circulatory system. To date, there are > 20 antiangiogenic drugs undergoing preclinical and clinical investigation alone and in conjunction with other treatment options to determine the validity of antiangiogenic agents in the treatment of prostate cancer. This article reviews several aspects of antiangiogenesis and its relationship to the treatment of prostate cancer.
Longoria
Ritchie L
RL
Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cox
Michael C
MC
Figg
William D
WD
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D011467:Prostate / Q000098:blood supply*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents